2892688-16-1
2892688-16-1
Chemical Structure
TKB245
- CAS No.: 2892688-16-1
- Formula:C30H35F4N5O5S
- Molecular Weight:653.69
InChIKey: UGXSZZAITMURED-MCUUEWDYSA-N
SMILES: O=C([C@@H]1[C@@]2([H])C(C)(C)[C@@]2([H])CN1C([C@@H](NC(C(F)(F)F)=O)C(C)(C)C)=O)N[C@@H](C[C@H]3C(NCC3)=O)C(C4=NC5=C(F)C=CC=C5S4)=O
Biological Activity: TKB245 is a highly potent SARS-CoV-2 Mpro inhibitor that effectively blocks SARS-CoV-2 replication in VeroE6 cells[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
TKB245 | 98.98% | TKB245 is a highly potent SARS-CoV-2 Mpro inhibitor that effectively blocks SARS-CoV-2 replication in VeroE6 cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Nirmatrelvir | 99.74% | Nirmatrelvir (PF-07321332) is a potent and orally active SARS-CoV 3C-like protease (3CLPRO) inhibitor. Nirmatrelvir (PF-07321332) targets to the SARS-CoV-2 virus and can be used for COVID-19 research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Nirmatrelvir-d6 | Nirmatrelvir-d6 (PF-07321332-d6) is deuterium labeled Nirmatrelvir. Nirmatrelvir (PF-07321332) is a potent and orally active SARS-CoV 3C-like protease (3CLPRO) inhibitor. Nirmatrelvir (PF-07321332) targets to the SARS-CoV-2 virus and can be used for COVID-19 research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
YH-53 | 98.78% | YH-53 is a potent 3CLpro inhibitor with Ki values of 6.3 nM, 34.7 nM for SARS-CoV-1 3CLpro and SARS-CoV-2 3CLpro, respectively. YH-53 strongly blocks the SARS-CoV-2 replication. YH-53 is a peptidomimetic compound with a unique benzothiazolyl ketone. YH-53 has the potential for COVID-19 research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SARS-CoV-2-IN-35 | SARS-CoV-2-IN-35 is a potent and orally active SARS-CoV-2 M pro inhibitor with a Ki value of 12.1 nM. SARS-CoV-2-IN-35 can be used in research of COVID-19. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SARS-CoV-2 3CLpro-IN-14 | SARS-CoV-2 3CLpro-IN-14 (compound 11j) is an orally active SARS-CoV-2 3CLpro inhibitor. SARS-CoV-2 3CLpro-IN-14 shows significant anti-SARS-CoV-2 activity (EC50 = 0.18 μM) and low cytotoxicity (CC50 > 50 μM) in Vero E6 cells. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Deunirmatrelvir | Deunirmatrelvir is a deuterium labeled compound. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ML2006a4 | ML2006a4 is an orally active inhibitor for SARS-CoV-2 main protease (Mpro) with IC50 in picomolare value. ML2006a4 is cell permeable and antiviral active, that inhibits replication in SARS-CoV-2 in cells Huh7.5.1-ACE2-TMPRSS2 (Huh7.5.1++) in picomolare level | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GRL-190-21 | GRL-190-21 (compound 5e) is an inhibitor for SARS-Cov-2-Mpro with a Ki of 0.04 nM and exhibits antiviral activity in VeroE6 cells with EC50 of 0.26 μM. GRL-190-21 reduces the infectivity, replication, and cytopathic effect of SARS-CoV-2 without significant toxicity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
TKB272 | TKB272 is an orally active and selective antiviral agent targeting the main protease (Mpro) of SARS-CoV-2. It effectively blocks the infection and replication of various SARS-CoV-2 strains, including Omicron variants such as XBB.1.5 and EG.5.1. The enzymatic inhibitory activity of TKB272 shows an IC50 of 0.7 µM (against SARS-CoV-2WK-521 Mpro), and its antiviral activity at the cellular level reaches an EC50 as low as 2.6 nM (against BQ.1.1 strain in HeLahACE2-TMPRSS2 cells), with a cytotoxicity CC50 of 98 µM, indicating no apparent toxicity. In addition, TKB272 significantly suppresses the replication of SARS-CoV-2XBB.1.5 in B6.Cg-Tg(K18-hACE2)2-Prlmn/J transgenic mouse models. TKB272 holds promise for research in the field of SARS-CoV-2 infection. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
VPC285785 | VPC285785 is an orally active SARS-CoV-2 main protease inhibitor with an IC50 of 0.8 μM and a Kd of 2.7 μM. VPC285785 functionally inhibits the viral main protease-mediated processing of viral polyprotein precursors required for viral replication. VPC285785 reduces viral loads in the liver, brain and spleen tissues of MHV-infected mice. VPC285785 is applicable to the research of coronavirus infections. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
